Abstract: Disclosed are novel antibody-drug conjugates and use thereof in therapy, in particular in anticancer or anti-inflammatory therapy, as well as synthetic products useful as linkers, composed of a linker head and a linker body, and also a method for preparing the linkers and the antibody-drug conjugates.

Abstract: Disclosed are novel antibody-drug conjugates and use thereof in therapy, in particular in anticancer or anti-inflammatory therapy, as well as synthetic products useful as linkers, composed of a linker head and a linker body, and also a method for preparing the linkers and the antibody-drug conjugates.

Abstract: Disclosed are novel antibody-drug conjugates and use thereof in therapy, in particular in anticancer or anti-inflammatory therapy, as well as synthetic products useful as linkers, composed of a linker head and a linker body, and also a method for preparing the linkers and the antibody-drug conjugates.

Abstract: A method is provided for encapsulating products that can have lipophilic or hydrophilic, including volatile, properties in a polysiloxane membrane that is particularly impervious. A method is also provided for evaluating the imperviousness of capsules. The present method includes the following steps: a) formation of droplets by an emulsion between an oily phase containing the product to be encapsulated and an acidic aqueous phase heated to around 50° C. and in the presence of surfactants; b) addition and hydrolysis of at least one silane in order to obtain a silanol; c) increasing the pH in order to start condensation of the silanol to form a first membrane around the droplets of the product to be encapsulated; d) lowering the pH; e) increasing the pH, optionally preceded by adding a silane, in order to obtain a new condensation of silanol around the droplets of the product to be encapsulated.

Abstract: Disclosed are novel antibody-drug conjugates and use thereof in therapy, in particular in anticancer or anti-inflammatory therapy, as well as synthetic products useful as linkers, composed of a linker head and a linker body, and also a method for preparing the linkers and the antibody-drug conjugates.

Abstract: A method is provided for encapsulating products that can have lipophilic or hydrophilic, including volatile, properties in a polysiloxane membrane that is particularly impervious. A method is also provided for evaluating the imperviousness of capsules. The present method includes the following steps: a) formation of droplets by an emulsion between an oily phase containing the product to be encapsulated and an acidic aqueous phase heated to around 50° C. and in the presence of surfactants; b) addition and hydrolysis of at least one silane in order to obtain a silanol; c) increasing the pH in order to start condensation of the silanol to form a first membrane around the droplets of the product to be encapsulated; d) lowering the pH; e) increasing the pH, optionally preceded by adding a silane, in order to obtain a new condensation of silanol around the droplets of the product to be encapsulated.

Abstract: The invention concerns molecules with a bis-(heteroaryl)maleimide structure and having inhibiting characteristics with respect to enzymes with a catalytic pocket comprising the invariant amino acids D, D and E or D, D and D, such as transposases, RAG recombinases or retroviral integrases. The invention also concerns the use of said molecules for in vitro, ex vivo or in vivo inhibition of transposases, RAG recombinases and retroviral integrases such as HIV integrase, as well as the use of said molecules in the treatment of diseases associated with these enzymes in an animal or human host, in particular in the treatment of AIDS.

Abstract: Compounds of formula (I): wherein: R1, R2, R3, R4 and X are as defined in the description, A represents an alkylene chain as defined in the description, B represents an alkyl or alkenyl group substituted by a group or R7, or B represents a group or R7. Medicinal products containing the same which are useful as hypoglycaemic and hypolipaemic agents.

Abstract: The invention relates to compounds of formula (I): wherein: G1 represents an alkylene chain as defined in the description, A represents R2 and R3 represent hydrogen, alkyl, alkoxy or hydroxy or together form oxo, R4 and R5 represent hydrogen, R1 is as defined in the description, and medicinal products containing the same which are useful in treating or preventing melatoninergic disorders.

Abstract: The invention relates to compound of formula (I) wherein: B represents hydrogen, COOR, CONRR?, or (C1-C6)alkyl substituted by COOR, CONRR?, or OR, G1 represents —X?—(CH2)n—X—(CH2)m—X?— chain wherein X, X?, X?, n and m are as defined in the description, Cy represents a grouping of formula (II) or (III): G2 represents alkylene chain as defined in the description, and A represents NRCOR?, NRCSR?, CONRR?, CSNRR?, NRCONR?R?, or NRCSNR?R?. and medicinal products containing the same which are useful in treating or preventing melatoninergic disorders.

Abstract: The invention concerns compounds of formula (1): R-A-R? wherein: A is as defined in the description; R represent a group (V), (VI), (VII), or (VIII), where E, Q, R1, R2, R3, v and R4 are as defined in the description; R? represents a —(CH2)t—R5 group wherein t and R5 are as defined in the description, and medicaments containing the same

Abstract: The invention relates to compounds of formula (I): wherein: B represents a hydrogen atom, a COOR group, a CONRR? group, or a (C1–C6)alkyl group substituted by a COOR, CONRR? or OR group, G1 represents a —X?—(CH2)n—X—(CH2)m—X?— chain wherein X, X?, X?, n and m are as defined in the description, Cy represents a grouping of formula (II) or (III): G2 represents an alkylene chain as defined in the description, and A represents a NRCOR?, NRCSR?, CONRR?, CSNRR?, NRCONR?R? or NRCSNR?R? group.

Abstract: The invention concerns compounds of formula (I): R-A-R? wherein: A is as defined in the description; R represents a group (V), (VI), (VII) or (VIII), where E, Q, R1, R2, R3, v and R4 are as defined in the description; R? represents a —(CH2)t-R5 group wherein t and R5 are as defined in the description

Abstract: The invention concerns compounds of formula (I): R—A—R? wherein: A is as defined in the description; R represents a group (V), (VI), (VII) or (VIII), where E, Q, R1, R2, R3, v and R4 are as defined in the description; R? represents a —(CH2)t-R5 group wherein t and R5 are as defined in the description.

Abstract: The invention concerns compounds of formula (I): R-A-R? wherein: A is as defined in the description; R represents a group (V), (VI), (VII) or (VIII), where E, Q, R1, R2, R3, v and R4 are as defined in the description; R? represents a —(CH2)t-R5 group wherein t and R5 are as defined in the description.

Abstract: The invention concerns compounds of formula (I): R—A—R? wherein: A is as defined in the description; R represent, a group (V), wherein R?a and R?a are as defined in the description, or R forms with A a cyclic structure as defined in the description; R? represents a (CH2)t—R2 group wherein q, t, and R2 are as defined in the description. The invention is useful for preparing medicines.

Abstract: The invention concerns compounds of formula (I): R-A-R? wherein: A is as defined in the description; R represents a group (V), (VI), (VII) or (VIII), where E, Q, R1, R2, R3, v and R4 are as defined in the description; R? represents a —(CH2)t-R5 group wherein t and R5 are as defined in the description.

Abstract: The invention relates to compound of formula (I): 1

Abstract: The invention concerns compounds of formula (I): R-A-R′ wherein: A is as defined in the description; R represent a group (V), (VI), (VII), or (VIII), where E, Q, R1, R2, R3, v and R4 are as defined in the description; R′ represents a —(CH2)t—R5 group wherein t and R5 are as defined in the description, and medicaments containing the same.

Abstract: The invention concerns compounds of formula (1): R-A-R′ wherein: A is as defined in the description; R represent a group (V), (VI), (VII), or (VIII), where E, Q, R1, R2, R3, v and R4 are as defined in the description; R′ represents a —(CH2)t—R5 group wherein t and R5 are as defined in the description, and medicaments containing the same.